Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, October 21, 2015

October Update- Upcoming and Recruiting Hepatitis C Clinical Trials

Upcoming and Recruiting Hepatitis C Clinical Trials

The HCV clinical trials in this post are not a complete list; to learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.

For a quick reference guide of drugs under development and FDA approved medications please visit:

HCV Advocate
Detailed Reference Guide
FDA Approved Medications
Phase II Clinical Trials
Phase III Clinical Trials

Of Interest
The 66th Liver Meeting of the American Association for the Study of Liver Diseases will take place in San Francisco, California between 13th and 17th November 2015, view late breaking abstracts, here. get updates of the meeting on twitter, here, or follow AASLD tweets, here.

This study is currently recruiting participants
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
ClinicalTrials.gov Identifier:
NCT02442284
Conditions: Chronic Hepatitis C; Cirrhosis; Hepatitis C Virus
Interventions: Drug: Ombitasvir; Drug: Paritaprevir; Drug: Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Verified October 2015 by AbbVie

This study is currently recruiting participants.
ClinicalTrials.gov Identifier:
NCT02582658
‎Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Recruiting - verified October 2015

New
This study is currently recruiting participants
‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C, Genotype 1 or 4
Intervention:
Sponsor: AbbVie
Recruiting - verified October 2015 

This study is currently recruiting participants.
United States, New York, France
ClinicalTrials.gov Identifier:
NCT02493855
Conditions: Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1a
Interventions: Drug: ombitasvir/ABT-450/ritonavir; Drug: dasabuvir; Drug: ribavirin
Verified October 2015 by AbbVie

This study is currently recruiting participants.
China
‎Monday, ‎October ‎12, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C Infection
Interventions: Drug: SOF+DCV; Drug: LDV/SOF
Sponsors: Humanity & Healthy GI and Liver Centre; Beijing 302 Hospital
Recruiting - verified October 2015 

This study is currently recruiting participants
India
Saturday, ‎September ‎26, ‎2015, ‏‎12:00:00 PM
Condition: CKD With Hepatitis C
Intervention:
Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting - verified September 2015 

This study is currently recruiting participants
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
ClinicalTrials.gov Identifier:
NCT02442271
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Verified October 2015 by AbbVie

This study is currently recruiting participants
ClinicalTrials.gov Identifier:
NCT02421211
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir (SMV); Drug: Ledipasvir (LDV); Drug: Sofosbuvir (SOF)
Sponsor: Janssen Sciences Ireland UC
Verified September 2015

This study is currently recruiting participants
A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection
ClinicalTrials.gov Identifier:
NCT01939197
Conditions: Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhotics
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin (RBV)
Verified October 2015 by AbbVie

This study is currently recruiting participants
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
United States, Maryland
ClinicalTrials.gov Identifier:
NCT01888900
Verified February 2015 by National Institutes of Health Clinical Center (CC)
Drug: Asunaprevir and Daclatsvir
Drug: Asunaprevir, daclatsvir, peginterferon, ribavirin

This study is not yet open for participant recruitment
Thursday, ‎October ‎01, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335; Drug: ACH-3102; Drug: Simeprevir
Sponsor: Alios Biopharma Inc.
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
‎Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02582632
Conditions: Hepatitis C Infection; Hepatitis C Virus
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: dasabuvir
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

New
This study is not yet open for participant recruitment
Yesterday, ‎October ‎20, ‎2015, ‏‎12:00:00 PM
Condition: Chronic Hepatitis C
Intervention:
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

ClinicalTrials.gov Identifier:
NCT02581020
‎Monday, ‎October ‎19, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C Virus
Intervention:
Sponsor: AbbVie
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment
Friday, ‎October ‎16, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Intervention: Drug: Daclatasvir plus Asunaprevir
Sponsors: Myeong Jun Song; Bristol-Myers Squibb; Soonchunhyang University Hospital; Dankook University; Chungnam National University Hospital; Konyang University Hospital; Eulji University Hospital; Saint Vincent's Hospital, Korea; Konkuk University Hospital; Cheongju St. Mary's Hospital, Cheongju, Korea; Severance Hospital; Korea University Guro Hospital; Eulji General Hospital
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment
A Drug-drug Interaction Study Between Daclatasvir and Metformin
ClinicalTrials.gov Identifier:
NCT02565862
‎Wednesday, ‎September ‎30, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis C; Diabetes Mellitus; Insulin Resistance
Interventions: Drug: Daclatasvir; Drug: Metformin
Sponsor: Radboud University
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
ClinicalTrials.gov Identifier:
NCT02565888‎
Wednesday, ‎September ‎30, ‎2015, ‏‎12:00:00 PM
Conditions: Hepatitis C; HIV
Interventions: Drug: Daclatasvir; Drug: Atazanavir; Drug: Ritonavir; Drug: Cobicistat
Sponsor: Radboud University
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
ClinicalTrials.gov Identifier:
NCT02562742
‎Monday, ‎September ‎28, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: SOF; Drug: REB
Sponsors: Gilead Sciences; Merck Sharp & Dohme Corp. Japan
Not yet recruiting - verified September 2015 

This study is not yet open for participant recruitment
‎Tuesday, ‎September ‎15, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: Daclatasvir; Drug: Sofosbuvir
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified October 2015 

This study is not yet open for participant recruitment
Tuesday, ‎September ‎15, ‎2015, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: Daclatasvir; Drug: Sofosbuvir; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified September 2015

No comments:

Post a Comment